Maternal methyldopa treatment and neonatal blood pressure Methyldopa is widely used to treat hypertension in pregnancy. Redman et all reported a controlled trial in which fetal loss in hypertensive patients was reduced in a group given methyldopa compared with an untreated group. Methyldopa is readily transferred across the placenta, and Jones et a12 found cord blood concentrations to be as high as maternal plasma concentrations. The drug is eliminated by sulphation and excretion and is detectable in neonatal plasma up to four days after birth.2 It produces modest reductions in blood pressure (5-6 mm Hg) in normotensive people, though much greater reductions occur in hypertensive adults with high plasma renin concentrations.3 Interference with a newborn infant's vasomotor control might have serious consequences if the infant was also affected by hypoxia, hypovolaemia, or cardiac disease, as perfusion of vital organs might be impaired. This study was aimed at determining whether systolic blood pressure was lower in infants of mothers treated with methyldopa than in infants of the same birth weight whose mothers had not received hypotensive drugs.
Patients, methods, and results
Over about 12 months 24 mothers given methyldopa were delivered after 37 or more weeks of gestation. The indications for treatment were either long-standing hypertension before pregnancy treated with an antihypertensive drug or a diastolic blood pressure consistently higher than 95 mm Hg before 28 weeks of pregnancy. The dose of methyldopa ranged from 500 mg to 2 g a day. Systolic.blood pressure was measured in the newborn infants at 12, 36, 60, 84, and 108 hours after delivery using a 5 cm wide Pedisphyg cuff, Parks Doppler blood-flow detector, and mercury sphygmomanometer. The Pedisphyg and Parks Doppler system have been validated against direct intra-arterial pressure measurements in infants (r 099).4 The cuff was applied to the right arm and the systolic blood pressure measured when the baby was awake, quiet, and not being fed. Duplicate measuremenits were made by one or two specially trained nursing sisters. Mean interobserver difference was 3-1 mm Hg, but there was no consistent bias.
The 24 full-term infants of the mothers treated with methyldopa were compared with a group of 50 randomly selected full-term infants whose mothers had not received antihypertensive drugs. Resting systolic blood pressure was measured in the control infants in the same way as in the infants of mothers treated with methyldopa. The table shows that birth weight and gestational age were not significantly different between the two groups.
The systolic blood pressure in the full-term infants of mothers given methyldopa was 4 5 and 4 3 mm Hg lower than the control blood pressure during days 1 and 2 respectively. By days 3, 4, and 5 there was no significant difference bctween the two groups. None of the infants of mothers treated with methyldopa showed a heart rate of below 120/minute. Three of these infants were tilted from horizontal to vertical while blood pressure and heart rate were measured; no change in cither variable was found.
There were three cascs of fetal distress in labour at term (type II fetal heart decelerations), but all of these babies had one-minute Apgar scores of six or more and were in good condition. Three of the 24 babies had one-minute Apgar scores below six, but all had an Apgar score of seven or more by five minutes.
Comment
These results show that the full-term infants of mothers treated with methyldopa had a significantly reduced systolic blood pressure during the first two days after delivery. The decrease in blood pressure (4-5 mm Hg) was comparable with that found when methyldopa is administered to normotensive adults.3 The duration of decreased blood pressure was consistent with the slow elimination of the drug by the neonate, normal blood pressures being achieved by about three days, when plasma methyldopa concentrations are low. The mild reduction in blood pressure should not seriously compromise the babies, and there was no evidence that their cardiovascular systems were unable to respond to stress. Before admission she had been taking dihydrocodeine tartrate two tablets four to six hourly. Three weeks before admission she had started taking dipipanone, which had been gradually increased to 20 mg four hourly. Four days before operation the pain intensified. She was given papaveretum 10 mg four hourly for two days, then pethidine 50 mg two hourly, then morphine 15 mg three hourly, which resulted in only partial pain relief. About 36 hours after starting morphine she underwent right profundoplasty and lumbar sympathectomy. At operation she was given additive-free, preservative-free morphine 2 mg intrathecally at the L2-3 interspace. This gave complete postoperative pain relief.
Having been well for two days, on the third postoperative day she became confused and disorientated. The next day she was restless and drowsy and looked pale and tired. She experienced visual and auditory hallucinations. She became anorexic and incontinent and had insomnia. She made several confused preparations to discharge herself from the hospital. By the end of the fifth postoperative day she was apparently normal. There was no further distress or hallucinations. Her appetite returned and she left hospital on the twelfth postoperative day.
Physical dependence on a drug is an altered physiological state produced by the repeated administration of that drug to prevent the appearance of a stereotypical syndrome. The time required to produce
